Olufunmilayo I Olopade


Affiliation: University of Chicago
Country: USA


  1. Guindalini R, Zheng Y, Abe H, Whitaker K, Yoshimatsu T, Walsh T, et al. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019;25:1786-1794 pubmed publisher
    ..No benefit was associated with annual MG screening plus biannual MRI screening.See related commentary by Kuhl and Schrading, p. 1693. ..
  2. Karginova O, Weekley C, Raoul A, Alsayed A, Wu T, Lee S, et al. Inhibition of Copper Transport Induces Apoptosis in Triple Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019;: pubmed publisher
    ..These data demonstrate that inhibition of intracellular copper transport targets tumor cells and the tumor microenvironment, and is a promising approach to treat breast cancer. ..
  3. Pitt J, Riester M, Zheng Y, Yoshimatsu T, Sanni A, Oluwasola O, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018;9:4181 pubmed publisher
    ..This dataset provides novel insights into potential molecular mechanisms underlying outcome disparities and lay a foundation for deployment of precision therapeutics in underserved populations. ..
  4. Han Y, Boatman S, Zhang J, Du X, Yeh A, Zheng Y, et al. LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Sci Rep. 2018;8:15572 pubmed publisher
    ..Our results suggest that increased expression of BLAT1 via CpG site hypomethylation may contribute to the aggressive phenotype of BLBC, raising a possibility of new biomarkers for prognosis of aggressive BLBC tumors. ..
  5. Pitt J, Zheng Y, Olopade O. Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. Cancer Cell. 2018;34:529-530 pubmed publisher
    ..They determined that the latter group has a propensity for aberrations that are consistent with genomic instability, potentially lending insight to the genomic basis of cancer health disparities. ..
  6. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015;17:61 pubmed publisher
    ..This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects. ..
  7. request reprint
    Olopade O, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003;3:417-20 pubmed
    ..Disruption of the pathway occurs de novo in ovarian cancers and may contribute to selective sensitivity to platinum salts. ..
  8. Olopade O, Grushko T, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14:7988-99 pubmed publisher
    ..The five articles in this edition of CCR Focus highlight recent advances and future directions on the pathway to individualized approaches for the early detection, treatment, and prevention of breast cancer. ..
  9. Silvestri V, Barrowdale D, Mulligan A, Neuhausen S, Fox S, Karlan B, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18:15 pubmed publisher
    ..e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management. ..

More Information


  1. West A, Blazer K, Stoll J, Jones M, Weipert C, Nielsen S, et al. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018;17:495-505 pubmed publisher
  2. Felix G, Zheng Y, Olopade O. Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer. 2018;17:471-483 pubmed publisher